| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Viral Envelope Proteins | 33 | 2023 | 207 | 8.250 |
Why?
|
| Virus Internalization | 18 | 2022 | 88 | 5.330 |
Why?
|
| Cytomegalovirus | 23 | 2022 | 482 | 5.260 |
Why?
|
| Simplexvirus | 12 | 2023 | 159 | 4.310 |
Why?
|
| Viral Proteins | 17 | 2020 | 435 | 4.130 |
Why?
|
| Virion | 16 | 2023 | 161 | 3.840 |
Why?
|
| Herpesvirus 1, Human | 14 | 2020 | 113 | 3.340 |
Why?
|
| Axons | 8 | 2023 | 403 | 3.160 |
Why?
|
| Multiple Myeloma | 38 | 2020 | 2138 | 2.710 |
Why?
|
| Capsid | 9 | 2021 | 103 | 2.630 |
Why?
|
| Axonal Transport | 6 | 2023 | 38 | 2.190 |
Why?
|
| Cell Cycle Proteins | 24 | 2011 | 2045 | 1.970 |
Why?
|
| Herpesviridae | 4 | 2021 | 42 | 1.970 |
Why?
|
| Anterior Cruciate Ligament Injuries | 11 | 2023 | 52 | 1.930 |
Why?
|
| E2F1 Transcription Factor | 25 | 2012 | 206 | 1.920 |
Why?
|
| Viral Fusion Proteins | 4 | 2021 | 85 | 1.840 |
Why?
|
| Lipoproteins | 5 | 2020 | 252 | 1.750 |
Why?
|
| Anterior Cruciate Ligament Reconstruction | 10 | 2022 | 18 | 1.670 |
Why?
|
| Membrane Glycoproteins | 13 | 2022 | 1073 | 1.650 |
Why?
|
| Cystectomy | 7 | 2020 | 623 | 1.630 |
Why?
|
| Cytomegalovirus Infections | 8 | 2019 | 462 | 1.580 |
Why?
|
| Prostatic Neoplasms | 14 | 2021 | 5767 | 1.570 |
Why?
|
| Epithelial Cells | 16 | 2019 | 1818 | 1.520 |
Why?
|
| Fee-for-Service Plans | 2 | 2021 | 40 | 1.490 |
Why?
|
| DNA-Binding Proteins | 27 | 2011 | 4821 | 1.460 |
Why?
|
| Cytoplasm | 8 | 2023 | 652 | 1.380 |
Why?
|
| Prostatectomy | 6 | 2021 | 962 | 1.290 |
Why?
|
| Neurons | 5 | 2021 | 2287 | 1.260 |
Why?
|
| Keratinocytes | 16 | 2014 | 241 | 1.250 |
Why?
|
| Cell Line | 27 | 2023 | 5114 | 1.240 |
Why?
|
| Carrier Proteins | 16 | 2014 | 2022 | 1.160 |
Why?
|
| Transcription Factors | 24 | 2016 | 5270 | 1.130 |
Why?
|
| Urinary Bladder Neoplasms | 9 | 2020 | 2341 | 1.130 |
Why?
|
| Thalidomide | 4 | 2017 | 569 | 1.100 |
Why?
|
| Virus Assembly | 4 | 2020 | 51 | 1.100 |
Why?
|
| Herpesviridae Infections | 2 | 2021 | 175 | 1.090 |
Why?
|
| Glycoproteins | 9 | 2014 | 747 | 1.060 |
Why?
|
| Endothelial Cells | 7 | 2022 | 1048 | 1.050 |
Why?
|
| E2F Transcription Factors | 21 | 2006 | 132 | 0.990 |
Why?
|
| Polymorphism, Single Nucleotide | 25 | 2019 | 4549 | 0.970 |
Why?
|
| Nuclear Envelope | 4 | 2021 | 39 | 0.930 |
Why?
|
| Nephrectomy | 5 | 2019 | 779 | 0.920 |
Why?
|
| Histocompatibility Antigens Class II | 5 | 2005 | 182 | 0.910 |
Why?
|
| Phosphoproteins | 6 | 2017 | 1152 | 0.910 |
Why?
|
| Herpesvirus 1, Suid | 1 | 2023 | 3 | 0.910 |
Why?
|
| Prostate | 4 | 2020 | 1088 | 0.900 |
Why?
|
| Intercellular Junctions | 4 | 2014 | 54 | 0.870 |
Why?
|
| Kidney Neoplasms | 9 | 2020 | 3022 | 0.860 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 6 | 2020 | 1265 | 0.840 |
Why?
|
| Proto-Oncogene Proteins c-myc | 8 | 2016 | 810 | 0.830 |
Why?
|
| Humans | 175 | 2023 | 261506 | 0.820 |
Why?
|
| Fibroblasts | 12 | 2018 | 1682 | 0.750 |
Why?
|
| trans-Golgi Network | 3 | 2021 | 11 | 0.750 |
Why?
|
| Reoperation | 11 | 2022 | 1382 | 0.740 |
Why?
|
| Viral Matrix Proteins | 1 | 2021 | 201 | 0.730 |
Why?
|
| Herpes Simplex | 1 | 2020 | 95 | 0.720 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2018 | 3552 | 0.700 |
Why?
|
| Urinary Diversion | 2 | 2018 | 69 | 0.700 |
Why?
|
| Genetic Predisposition to Disease | 19 | 2019 | 5539 | 0.690 |
Why?
|
| Animals | 70 | 2023 | 59536 | 0.690 |
Why?
|
| Cytoplasmic Vesicles | 1 | 2018 | 9 | 0.670 |
Why?
|
| Vero Cells | 8 | 2017 | 143 | 0.670 |
Why?
|
| Basigin | 1 | 2018 | 20 | 0.650 |
Why?
|
| Fires | 1 | 2018 | 22 | 0.640 |
Why?
|
| Robotic Surgical Procedures | 3 | 2020 | 481 | 0.640 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2003 | 235 | 0.630 |
Why?
|
| Protein Multimerization | 4 | 2018 | 240 | 0.620 |
Why?
|
| Osteoarthritis | 3 | 2023 | 94 | 0.610 |
Why?
|
| Ablation Techniques | 1 | 2019 | 148 | 0.610 |
Why?
|
| Membrane Fusion | 4 | 2021 | 51 | 0.600 |
Why?
|
| Genes, Tumor Suppressor | 5 | 2013 | 1064 | 0.600 |
Why?
|
| Apoptosis | 14 | 2016 | 7591 | 0.590 |
Why?
|
| Molecular Chaperones | 2 | 2009 | 264 | 0.580 |
Why?
|
| Capsid Proteins | 3 | 2012 | 185 | 0.580 |
Why?
|
| Carcinoma, Transitional Cell | 4 | 2018 | 962 | 0.580 |
Why?
|
| Protein Transport | 6 | 2020 | 734 | 0.560 |
Why?
|
| Promoter Regions, Genetic | 16 | 2018 | 3101 | 0.550 |
Why?
|
| Preoperative Care | 3 | 2019 | 1529 | 0.550 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2019 | 2326 | 0.540 |
Why?
|
| Tumor Burden | 4 | 2020 | 1987 | 0.540 |
Why?
|
| Tumor Suppressor Protein p14ARF | 3 | 2006 | 97 | 0.520 |
Why?
|
| Gene Frequency | 2 | 2017 | 1163 | 0.520 |
Why?
|
| DNA Repair | 3 | 2012 | 1872 | 0.520 |
Why?
|
| Cells, Cultured | 15 | 2018 | 5637 | 0.510 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 15 | 2000 | 54 | 0.510 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 179 | 0.510 |
Why?
|
| Male | 67 | 2023 | 123000 | 0.500 |
Why?
|
| Endoplasmic Reticulum | 5 | 2009 | 308 | 0.490 |
Why?
|
| Nucleosides | 2 | 2004 | 60 | 0.490 |
Why?
|
| Thinness | 1 | 2014 | 82 | 0.480 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2007 | 1555 | 0.480 |
Why?
|
| Transcription Factor DP1 | 14 | 2000 | 57 | 0.480 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 196 | 0.470 |
Why?
|
| Herpesvirus 2, Human | 2 | 2020 | 24 | 0.470 |
Why?
|
| Patient Preference | 1 | 2016 | 218 | 0.470 |
Why?
|
| Serum Albumin | 1 | 2014 | 257 | 0.470 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2014 | 187 | 0.470 |
Why?
|
| Antigen Presentation | 2 | 2005 | 272 | 0.460 |
Why?
|
| Immunologic Factors | 1 | 2017 | 649 | 0.460 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2022 | 134 | 0.460 |
Why?
|
| Gene Deletion | 6 | 2018 | 1442 | 0.450 |
Why?
|
| Retinoblastoma Protein | 10 | 2010 | 335 | 0.450 |
Why?
|
| Skin Neoplasms | 11 | 2013 | 4654 | 0.440 |
Why?
|
| Brugada Syndrome | 2 | 2023 | 18 | 0.440 |
Why?
|
| Cell Fusion | 2 | 2012 | 80 | 0.440 |
Why?
|
| Gene Expression Profiling | 12 | 2020 | 5159 | 0.440 |
Why?
|
| Genome-Wide Association Study | 10 | 2019 | 2265 | 0.440 |
Why?
|
| Mutation | 17 | 2018 | 15179 | 0.430 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2013 | 1823 | 0.430 |
Why?
|
| Mice, Transgenic | 18 | 2009 | 4143 | 0.420 |
Why?
|
| Patient Participation | 1 | 2016 | 446 | 0.420 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 622 | 0.420 |
Why?
|
| Cell Cycle | 7 | 2011 | 2084 | 0.420 |
Why?
|
| Cells | 1 | 2012 | 31 | 0.420 |
Why?
|
| Transcription, Genetic | 9 | 2006 | 3154 | 0.420 |
Why?
|
| Water Purification | 2 | 2021 | 18 | 0.410 |
Why?
|
| Genotype | 10 | 2021 | 4109 | 0.410 |
Why?
|
| Adenoviridae | 5 | 2009 | 1459 | 0.400 |
Why?
|
| Malnutrition | 1 | 2014 | 218 | 0.400 |
Why?
|
| Virus Release | 1 | 2011 | 12 | 0.400 |
Why?
|
| Patient Selection | 1 | 2019 | 2055 | 0.400 |
Why?
|
| Arthroscopy | 1 | 2011 | 57 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 16 | 2016 | 8873 | 0.390 |
Why?
|
| Joint Diseases | 1 | 2011 | 71 | 0.380 |
Why?
|
| Biological Transport | 5 | 2018 | 597 | 0.380 |
Why?
|
| Gene Silencing | 6 | 2018 | 837 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2013 | 2359 | 0.380 |
Why?
|
| Cartilage, Articular | 2 | 2023 | 75 | 0.370 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2011 | 393 | 0.370 |
Why?
|
| Gene Expression Regulation | 10 | 2018 | 4053 | 0.370 |
Why?
|
| Protein Binding | 12 | 2018 | 3438 | 0.370 |
Why?
|
| Skin | 8 | 2013 | 1259 | 0.370 |
Why?
|
| Weight Loss | 1 | 2014 | 627 | 0.360 |
Why?
|
| Cytoreduction Surgical Procedures | 3 | 2019 | 475 | 0.360 |
Why?
|
| Aged | 38 | 2022 | 70117 | 0.360 |
Why?
|
| Mice | 38 | 2018 | 34495 | 0.360 |
Why?
|
| Cyclin-Dependent Kinases | 7 | 2004 | 311 | 0.360 |
Why?
|
| Translocation, Genetic | 7 | 2015 | 1245 | 0.360 |
Why?
|
| Rats | 10 | 2014 | 6086 | 0.350 |
Why?
|
| Health Care Costs | 1 | 2015 | 674 | 0.350 |
Why?
|
| Nuclear Proteins | 7 | 2019 | 3343 | 0.350 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2011 | 113 | 0.350 |
Why?
|
| Repressor Proteins | 5 | 2016 | 1664 | 0.350 |
Why?
|
| Hantavirus Infections | 1 | 2009 | 10 | 0.350 |
Why?
|
| Documentation | 1 | 2011 | 207 | 0.350 |
Why?
|
| DNA Damage | 5 | 2012 | 1954 | 0.340 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2005 | 1033 | 0.340 |
Why?
|
| Middle Aged | 38 | 2021 | 86204 | 0.340 |
Why?
|
| Genes, Viral | 2 | 2007 | 202 | 0.340 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 7702 | 0.330 |
Why?
|
| DNA | 5 | 2023 | 2693 | 0.330 |
Why?
|
| Keratitis, Herpetic | 2 | 2005 | 28 | 0.330 |
Why?
|
| E2F3 Transcription Factor | 1 | 2008 | 23 | 0.330 |
Why?
|
| Cyclins | 5 | 2004 | 456 | 0.330 |
Why?
|
| Cohort Studies | 12 | 2023 | 9244 | 0.320 |
Why?
|
| Decision Making | 1 | 2016 | 1287 | 0.320 |
Why?
|
| Virus Diseases | 1 | 2012 | 398 | 0.320 |
Why?
|
| HeLa Cells | 6 | 2018 | 1643 | 0.310 |
Why?
|
| Virus Physiological Phenomena | 2 | 2012 | 19 | 0.310 |
Why?
|
| RNA, Small Interfering | 3 | 2012 | 2216 | 0.310 |
Why?
|
| Female | 59 | 2022 | 141928 | 0.310 |
Why?
|
| Phosphorylation | 7 | 2021 | 4804 | 0.300 |
Why?
|
| Margins of Excision | 2 | 2019 | 285 | 0.300 |
Why?
|
| Genetic Vectors | 7 | 2009 | 1694 | 0.290 |
Why?
|
| Membrane Proteins | 4 | 2011 | 2819 | 0.290 |
Why?
|
| Genetic Association Studies | 4 | 2019 | 1084 | 0.290 |
Why?
|
| Image-Guided Biopsy | 2 | 2019 | 327 | 0.290 |
Why?
|
| Microscopy, Fluorescence | 5 | 2007 | 769 | 0.290 |
Why?
|
| Genes, MHC Class I | 1 | 2006 | 46 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2014 | 2488 | 0.280 |
Why?
|
| Transcriptome | 4 | 2020 | 1859 | 0.280 |
Why?
|
| Herpes Genitalis | 1 | 2006 | 17 | 0.280 |
Why?
|
| Gene Dosage | 3 | 2018 | 829 | 0.270 |
Why?
|
| Ganglia, Sensory | 1 | 2005 | 5 | 0.270 |
Why?
|
| Cyclin D1 | 5 | 2013 | 576 | 0.270 |
Why?
|
| Receptors, Virus | 2 | 2006 | 157 | 0.270 |
Why?
|
| Proteins | 6 | 2004 | 1963 | 0.270 |
Why?
|
| Immediate-Early Proteins | 2 | 2003 | 107 | 0.270 |
Why?
|
| Interferon Regulatory Factors | 2 | 2016 | 76 | 0.270 |
Why?
|
| Ureteral Neoplasms | 2 | 2018 | 228 | 0.270 |
Why?
|
| Viral Structural Proteins | 2 | 2020 | 47 | 0.260 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2018 | 164 | 0.260 |
Why?
|
| Antigens, CD1 | 1 | 2005 | 49 | 0.260 |
Why?
|
| Benzyl Compounds | 1 | 2004 | 10 | 0.260 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2019 | 799 | 0.260 |
Why?
|
| Case-Control Studies | 14 | 2020 | 6100 | 0.260 |
Why?
|
| Postoperative Complications | 4 | 2020 | 5542 | 0.260 |
Why?
|
| Nucleocapsid | 1 | 2004 | 12 | 0.260 |
Why?
|
| Corneal Stroma | 1 | 2005 | 80 | 0.250 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 384 | 0.250 |
Why?
|
| Herpesvirus 8, Human | 1 | 2005 | 102 | 0.250 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2017 | 467 | 0.250 |
Why?
|
| United States | 11 | 2023 | 15433 | 0.250 |
Why?
|
| Comet Assay | 3 | 2011 | 59 | 0.250 |
Why?
|
| Heat-Shock Proteins | 1 | 2006 | 311 | 0.250 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 1998 | 445 | 0.250 |
Why?
|
| Anterior Cruciate Ligament | 3 | 2022 | 35 | 0.250 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 1742 | 0.240 |
Why?
|
| Blotting, Western | 6 | 2016 | 3536 | 0.240 |
Why?
|
| Epidermis | 6 | 2004 | 188 | 0.240 |
Why?
|
| Polyphosphates | 1 | 2004 | 13 | 0.240 |
Why?
|
| Homozygote | 3 | 2019 | 717 | 0.240 |
Why?
|
| Cell Membrane | 6 | 2018 | 850 | 0.240 |
Why?
|
| Extinction, Psychological | 3 | 2015 | 31 | 0.230 |
Why?
|
| Genes, MHC Class II | 1 | 2003 | 67 | 0.230 |
Why?
|
| Genes, ras | 2 | 1998 | 667 | 0.230 |
Why?
|
| Tibial Meniscus Injuries | 2 | 2020 | 22 | 0.230 |
Why?
|
| Endocytosis | 3 | 2012 | 225 | 0.230 |
Why?
|
| Epithelium, Corneal | 1 | 2005 | 223 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 14 | 3 | 2013 | 272 | 0.220 |
Why?
|
| Models, Biological | 6 | 2012 | 3254 | 0.220 |
Why?
|
| Prognosis | 15 | 2020 | 21713 | 0.220 |
Why?
|
| Athletic Injuries | 2 | 2019 | 97 | 0.220 |
Why?
|
| Epithelium | 2 | 2021 | 720 | 0.220 |
Why?
|
| Retrospective Studies | 14 | 2023 | 37905 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2013 | 402 | 0.220 |
Why?
|
| Protein Structure, Tertiary | 4 | 2014 | 1487 | 0.220 |
Why?
|
| Cell Division | 8 | 2004 | 2489 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2014 | 234 | 0.210 |
Why?
|
| Neoplasms | 6 | 2023 | 15193 | 0.210 |
Why?
|
| Plasma Cells | 3 | 2018 | 192 | 0.210 |
Why?
|
| Virus Replication | 5 | 2014 | 709 | 0.210 |
Why?
|
| Drinking Water | 1 | 2021 | 21 | 0.210 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 446 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 2 | 2018 | 4975 | 0.210 |
Why?
|
| Oncogenes | 3 | 2007 | 673 | 0.210 |
Why?
|
| Cell Line, Tumor | 12 | 2019 | 14551 | 0.200 |
Why?
|
| Base Sequence | 13 | 2014 | 4917 | 0.200 |
Why?
|
| Fear | 3 | 2015 | 254 | 0.200 |
Why?
|
| Alleles | 5 | 2019 | 2437 | 0.200 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2021 | 36 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2016 | 476 | 0.200 |
Why?
|
| Immunoprecipitation | 2 | 2016 | 591 | 0.200 |
Why?
|
| Antigens, Viral | 3 | 2011 | 471 | 0.190 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2020 | 64 | 0.190 |
Why?
|
| Health Services | 1 | 2021 | 105 | 0.190 |
Why?
|
| Chromosomes, Human | 2 | 2013 | 295 | 0.190 |
Why?
|
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 2 | 1997 | 96 | 0.190 |
Why?
|
| S Phase | 3 | 2002 | 281 | 0.190 |
Why?
|
| Kidney | 2 | 2020 | 2146 | 0.190 |
Why?
|
| Adenosine Triphosphatases | 2 | 2019 | 435 | 0.190 |
Why?
|
| Chromosome Aberrations | 5 | 2020 | 1960 | 0.190 |
Why?
|
| Transfection | 9 | 2003 | 2944 | 0.180 |
Why?
|
| Sequence Deletion | 3 | 2010 | 875 | 0.180 |
Why?
|
| Antibodies, Neutralizing | 3 | 2022 | 541 | 0.180 |
Why?
|
| DNA Adducts | 2 | 1997 | 210 | 0.180 |
Why?
|
| Return to Sport | 1 | 2019 | 8 | 0.180 |
Why?
|
| Naltrexone | 1 | 2020 | 87 | 0.180 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2019 | 7 | 0.180 |
Why?
|
| Molecular Sequence Data | 11 | 2012 | 6089 | 0.170 |
Why?
|
| Valosin Containing Protein | 1 | 2019 | 14 | 0.170 |
Why?
|
| Firearms | 1 | 2020 | 41 | 0.170 |
Why?
|
| Quantitative Trait Loci | 5 | 2019 | 374 | 0.170 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 4988 | 0.170 |
Why?
|
| Cell Physiological Phenomena | 1 | 1999 | 24 | 0.170 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 129 | 0.170 |
Why?
|
| Logistic Models | 5 | 2018 | 3441 | 0.170 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2018 | 31 | 0.170 |
Why?
|
| Ureteroscopy | 1 | 2018 | 46 | 0.170 |
Why?
|
| Neuronal Plasticity | 2 | 2012 | 304 | 0.170 |
Why?
|
| Nephroureterectomy | 1 | 2018 | 39 | 0.170 |
Why?
|
| Cost Savings | 1 | 2019 | 123 | 0.170 |
Why?
|
| Wounds, Gunshot | 1 | 2020 | 102 | 0.160 |
Why?
|
| Swine | 1 | 2023 | 1541 | 0.160 |
Why?
|
| False Negative Reactions | 1 | 2018 | 275 | 0.160 |
Why?
|
| Proteostasis | 1 | 2019 | 52 | 0.160 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 411 | 0.160 |
Why?
|
| Adult | 24 | 2023 | 77950 | 0.160 |
Why?
|
| Sex Factors | 4 | 2021 | 2139 | 0.160 |
Why?
|
| Smoke | 1 | 2018 | 60 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 3 | 2009 | 2314 | 0.160 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 14289 | 0.160 |
Why?
|
| Genetic Drift | 1 | 2017 | 30 | 0.150 |
Why?
|
| Cell Nucleus | 2 | 2021 | 1620 | 0.150 |
Why?
|
| Length of Stay | 2 | 2015 | 1900 | 0.150 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2017 | 44 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 3890 | 0.150 |
Why?
|
| Chromosome Mapping | 4 | 2014 | 1471 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2017 | 6207 | 0.150 |
Why?
|
| Food Services | 1 | 2017 | 38 | 0.150 |
Why?
|
| Exome | 3 | 2017 | 1239 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2011 | 507 | 0.150 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 2006 | 226 | 0.150 |
Why?
|
| Frailty | 1 | 2019 | 113 | 0.150 |
Why?
|
| Oncogene Proteins | 2 | 2017 | 354 | 0.150 |
Why?
|
| Genetic Pleiotropy | 1 | 2017 | 29 | 0.150 |
Why?
|
| Medicare | 1 | 2022 | 860 | 0.150 |
Why?
|
| Health Expenditures | 1 | 2019 | 211 | 0.150 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2014 | 31 | 0.150 |
Why?
|
| Heterozygote | 2 | 2008 | 1020 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2000 | 493 | 0.150 |
Why?
|
| Food Preferences | 1 | 2017 | 119 | 0.140 |
Why?
|
| Medical Oncology | 2 | 2023 | 1423 | 0.140 |
Why?
|
| Menisci, Tibial | 3 | 2023 | 26 | 0.140 |
Why?
|
| Risk Factors | 11 | 2019 | 17523 | 0.140 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 429 | 0.140 |
Why?
|
| Immunohistochemistry | 7 | 2015 | 7548 | 0.140 |
Why?
|
| Counseling | 1 | 2019 | 381 | 0.140 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2016 | 31 | 0.140 |
Why?
|
| Loss of Heterozygosity | 5 | 2012 | 602 | 0.140 |
Why?
|
| Thymus Gland | 2 | 2009 | 294 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 259 | 0.140 |
Why?
|
| DNA Copy Number Variations | 2 | 2015 | 1516 | 0.140 |
Why?
|
| Signal Transduction | 7 | 2019 | 11965 | 0.140 |
Why?
|
| Mice, Knockout | 7 | 2013 | 5710 | 0.140 |
Why?
|
| Aged, 80 and over | 14 | 2020 | 29902 | 0.140 |
Why?
|
| Microscopy, Electron | 3 | 2012 | 600 | 0.130 |
Why?
|
| T-Lymphocytes | 2 | 2006 | 3869 | 0.130 |
Why?
|
| Genomic Instability | 1 | 2018 | 519 | 0.130 |
Why?
|
| Electrocardiography | 1 | 2021 | 1145 | 0.130 |
Why?
|
| Gene Expression | 6 | 2019 | 3570 | 0.130 |
Why?
|
| Fruit | 1 | 2017 | 294 | 0.130 |
Why?
|
| Urologic Neoplasms | 1 | 2017 | 188 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2018 | 2390 | 0.130 |
Why?
|
| Child Behavior | 1 | 2017 | 243 | 0.130 |
Why?
|
| Amidohydrolases | 1 | 2015 | 25 | 0.130 |
Why?
|
| Amino Acid Sequence | 7 | 2016 | 4233 | 0.130 |
Why?
|
| Prospective Studies | 8 | 2020 | 12873 | 0.130 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2013 | 247 | 0.130 |
Why?
|
| RNA Interference | 2 | 2012 | 1408 | 0.130 |
Why?
|
| Ileus | 1 | 2015 | 27 | 0.130 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2015 | 110 | 0.130 |
Why?
|
| Vegetables | 1 | 2017 | 325 | 0.130 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2008 | 430 | 0.130 |
Why?
|
| E2F4 Transcription Factor | 3 | 2000 | 30 | 0.130 |
Why?
|
| Recombinant Proteins | 3 | 2011 | 2927 | 0.130 |
Why?
|
| Histones | 3 | 2016 | 1466 | 0.130 |
Why?
|
| Cystoscopy | 1 | 2015 | 88 | 0.130 |
Why?
|
| Genes, p53 | 3 | 2011 | 1090 | 0.130 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 833 | 0.120 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 4892 | 0.120 |
Why?
|
| Ultraviolet Rays | 3 | 2006 | 575 | 0.120 |
Why?
|
| Computer-Assisted Instruction | 1 | 2015 | 81 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2015 | 108 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 3 | 2011 | 3976 | 0.120 |
Why?
|
| Family Relations | 1 | 2015 | 88 | 0.120 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2014 | 47 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 7 | 2013 | 3203 | 0.120 |
Why?
|
| DNA Mutational Analysis | 3 | 2017 | 2283 | 0.120 |
Why?
|
| Survival Rate | 6 | 2019 | 12221 | 0.120 |
Why?
|
| Frontal Lobe | 1 | 2015 | 187 | 0.120 |
Why?
|
| Blotting, Northern | 5 | 2011 | 682 | 0.120 |
Why?
|
| Amygdala | 1 | 2015 | 127 | 0.120 |
Why?
|
| Genes, Immunoglobulin | 2 | 1992 | 87 | 0.120 |
Why?
|
| Receptors, IgG | 1 | 2014 | 102 | 0.120 |
Why?
|
| RNA, Neoplasm | 2 | 2014 | 771 | 0.120 |
Why?
|
| Government Programs | 1 | 2013 | 15 | 0.120 |
Why?
|
| Cell Proliferation | 1 | 2006 | 7226 | 0.120 |
Why?
|
| Referral and Consultation | 2 | 2017 | 899 | 0.120 |
Why?
|
| Young Adult | 10 | 2020 | 21445 | 0.120 |
Why?
|
| Spouses | 1 | 2015 | 134 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 2594 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 9 | 2010 | 5395 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 703 | 0.120 |
Why?
|
| Hyperplasia | 3 | 2009 | 557 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2016 | 53 | 0.120 |
Why?
|
| Bicycling | 1 | 2013 | 38 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 4298 | 0.120 |
Why?
|
| Operative Time | 1 | 2014 | 217 | 0.110 |
Why?
|
| Transplantation, Autologous | 4 | 2021 | 1914 | 0.110 |
Why?
|
| Antibodies, Viral | 2 | 2011 | 1320 | 0.110 |
Why?
|
| Urinary Bladder | 1 | 2016 | 575 | 0.110 |
Why?
|
| HLA-D Antigens | 2 | 2003 | 32 | 0.110 |
Why?
|
| Transportation | 1 | 2013 | 50 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2018 | 769 | 0.110 |
Why?
|
| Knee Joint | 3 | 2019 | 161 | 0.110 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2013 | 35 | 0.110 |
Why?
|
| Epigenesis, Genetic | 3 | 2017 | 1399 | 0.110 |
Why?
|
| Lymph Node Excision | 2 | 2017 | 1959 | 0.110 |
Why?
|
| HLA-DR Antigens | 2 | 2003 | 173 | 0.110 |
Why?
|
| Neuroglia | 2 | 2005 | 223 | 0.110 |
Why?
|
| Clathrin | 1 | 2012 | 34 | 0.110 |
Why?
|
| Aotidae | 1 | 2012 | 28 | 0.110 |
Why?
|
| Administration, Intravesical | 1 | 2013 | 162 | 0.110 |
Why?
|
| Codon | 2 | 2011 | 241 | 0.110 |
Why?
|
| Dynamins | 1 | 2012 | 74 | 0.110 |
Why?
|
| Mass Spectrometry | 3 | 2015 | 702 | 0.110 |
Why?
|
| Chromosome Breakage | 1 | 2013 | 226 | 0.110 |
Why?
|
| Thrombosis | 1 | 2019 | 781 | 0.110 |
Why?
|
| Embryo, Mammalian | 2 | 2014 | 741 | 0.110 |
Why?
|
| Germinal Center | 1 | 2013 | 161 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2011 | 15862 | 0.110 |
Why?
|
| Adenoviruses, Human | 2 | 2003 | 181 | 0.100 |
Why?
|
| Cyclin E | 2 | 2007 | 267 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2012 | 108 | 0.100 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 1360 | 0.100 |
Why?
|
| Time Factors | 6 | 2019 | 12926 | 0.100 |
Why?
|
| Chromatin | 2 | 2018 | 942 | 0.100 |
Why?
|
| Dimerization | 2 | 2005 | 304 | 0.100 |
Why?
|
| Kaposi Varicelliform Eruption | 1 | 2011 | 4 | 0.100 |
Why?
|
| Injections, Intra-Articular | 1 | 2011 | 32 | 0.100 |
Why?
|
| Replication Protein A | 1 | 2011 | 35 | 0.100 |
Why?
|
| Superior Cervical Ganglion | 1 | 2011 | 18 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1995 | 803 | 0.100 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2007 | 189 | 0.100 |
Why?
|
| Anatomic Landmarks | 1 | 2011 | 50 | 0.100 |
Why?
|
| Phenotype | 7 | 2015 | 6295 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 551 | 0.100 |
Why?
|
| Quality of Life | 4 | 2022 | 4532 | 0.100 |
Why?
|
| Connexins | 1 | 2001 | 78 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 4 | 4 | 2004 | 198 | 0.100 |
Why?
|
| Genome, Human | 3 | 2015 | 1869 | 0.100 |
Why?
|
| ras Proteins | 1 | 2015 | 770 | 0.100 |
Why?
|
| Genetic Linkage | 2 | 2018 | 512 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 1375 | 0.100 |
Why?
|
| Immunoblotting | 3 | 2006 | 886 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2023 | 14889 | 0.100 |
Why?
|
| Dermatitis, Atopic | 1 | 2011 | 47 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 5687 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 945 | 0.100 |
Why?
|
| Rad51 Recombinase | 1 | 2011 | 126 | 0.100 |
Why?
|
| Body Mass Index | 2 | 2017 | 2203 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 1 | 2001 | 143 | 0.090 |
Why?
|
| Shoulder Joint | 1 | 2011 | 82 | 0.090 |
Why?
|
| Genetic Heterogeneity | 1 | 2012 | 318 | 0.090 |
Why?
|
| Viruses | 1 | 2012 | 159 | 0.090 |
Why?
|
| Radiation, Ionizing | 1 | 2011 | 187 | 0.090 |
Why?
|
| Treatment Outcome | 8 | 2020 | 32848 | 0.090 |
Why?
|
| Internet | 1 | 2015 | 706 | 0.090 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2012 | 287 | 0.090 |
Why?
|
| Clonal Evolution | 1 | 2012 | 253 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2011 | 311 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 1258 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 748 | 0.090 |
Why?
|
| DNA, Recombinant | 1 | 2009 | 121 | 0.090 |
Why?
|
| Conditioning, Classical | 1 | 2009 | 69 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2014 | 2232 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 509 | 0.090 |
Why?
|
| Viral Core Proteins | 1 | 2009 | 22 | 0.090 |
Why?
|
| Virus Integration | 1 | 2009 | 76 | 0.090 |
Why?
|
| Piperidines | 1 | 2015 | 1035 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2011 | 362 | 0.090 |
Why?
|
| Autophagy | 2 | 2019 | 927 | 0.090 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2016 | 362 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2011 | 585 | 0.090 |
Why?
|
| Genetic Testing | 2 | 2023 | 1589 | 0.090 |
Why?
|
| Mesocricetus | 1 | 2009 | 114 | 0.090 |
Why?
|
| DNA Methylation | 3 | 2016 | 2669 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2006 | 528 | 0.080 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2011 | 310 | 0.080 |
Why?
|
| Caregivers | 1 | 2015 | 677 | 0.080 |
Why?
|
| Keratins | 2 | 2001 | 330 | 0.080 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2011 | 316 | 0.080 |
Why?
|
| Survival Analysis | 4 | 2017 | 9180 | 0.080 |
Why?
|
| Pyrazines | 1 | 2011 | 495 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 1209 | 0.080 |
Why?
|
| Bromodeoxyuridine | 2 | 2001 | 139 | 0.080 |
Why?
|
| Trans-Activators | 2 | 2001 | 1555 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 598 | 0.080 |
Why?
|
| DNA, Viral | 2 | 2018 | 694 | 0.080 |
Why?
|
| Imatinib Mesylate | 1 | 2012 | 1665 | 0.080 |
Why?
|
| Risk | 3 | 2018 | 1972 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 1429 | 0.080 |
Why?
|
| Cricetinae | 1 | 2009 | 706 | 0.080 |
Why?
|
| Adolescent | 9 | 2021 | 31252 | 0.080 |
Why?
|
| Age Factors | 4 | 2020 | 5377 | 0.080 |
Why?
|
| Comorbidity | 1 | 2014 | 2352 | 0.080 |
Why?
|
| Binding Sites | 4 | 2014 | 2171 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2012 | 2063 | 0.080 |
Why?
|
| Hemostasis | 1 | 2008 | 109 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 611 | 0.080 |
Why?
|
| Tooth Crown | 1 | 2007 | 1 | 0.080 |
Why?
|
| Orthodontics, Corrective | 1 | 2007 | 2 | 0.080 |
Why?
|
| Incisor | 1 | 2007 | 9 | 0.080 |
Why?
|
| Retinoblastoma-Like Protein p130 | 2 | 1998 | 18 | 0.080 |
Why?
|
| Gingiva | 1 | 2007 | 18 | 0.080 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2018 | 518 | 0.080 |
Why?
|
| Cytidine Deaminase | 2 | 2019 | 83 | 0.080 |
Why?
|
| Rabbits | 3 | 2022 | 957 | 0.080 |
Why?
|
| Genetic Variation | 2 | 2015 | 2086 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2013 | 1353 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2019 | 6869 | 0.070 |
Why?
|
| Hemagglutinins, Viral | 1 | 2006 | 45 | 0.070 |
Why?
|
| Benzamides | 1 | 2012 | 1832 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 644 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 260 | 0.070 |
Why?
|
| Golgi Apparatus | 1 | 2007 | 147 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 152 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 2 | 2021 | 993 | 0.070 |
Why?
|
| Anxiety Disorders | 1 | 2012 | 666 | 0.070 |
Why?
|
| Biomarkers, Tumor | 4 | 2020 | 10331 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 2864 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 1299 | 0.070 |
Why?
|
| Oxidoreductases | 1 | 2007 | 171 | 0.070 |
Why?
|
| Administration, Intravaginal | 1 | 2006 | 10 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 4367 | 0.070 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2006 | 33 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1998 | 261 | 0.070 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 3719 | 0.070 |
Why?
|
| Viral Vaccines | 1 | 2009 | 304 | 0.070 |
Why?
|
| Memory | 1 | 2009 | 429 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2007 | 254 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2011 | 5437 | 0.070 |
Why?
|
| Mutagenesis | 2 | 2006 | 483 | 0.070 |
Why?
|
| Receptors, Androgen | 1 | 2011 | 878 | 0.070 |
Why?
|
| Data Collection | 1 | 2008 | 620 | 0.070 |
Why?
|
| Ataxia Telangiectasia | 1 | 2006 | 62 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2007 | 448 | 0.070 |
Why?
|
| Lymphocyte Subsets | 1 | 2005 | 137 | 0.070 |
Why?
|
| Epigenomics | 2 | 2017 | 266 | 0.070 |
Why?
|
| Hydrogenation | 1 | 2004 | 3 | 0.070 |
Why?
|
| Ethers | 1 | 2004 | 14 | 0.060 |
Why?
|
| Smoking | 1 | 2014 | 2440 | 0.060 |
Why?
|
| Exons | 3 | 2009 | 1328 | 0.060 |
Why?
|
| Fluorescence | 1 | 2005 | 195 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2006 | 429 | 0.060 |
Why?
|
| Lymphocytes | 1 | 1990 | 1234 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 459 | 0.060 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2004 | 28 | 0.060 |
Why?
|
| RNA, Messenger | 5 | 2014 | 6150 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2006 | 471 | 0.060 |
Why?
|
| Mutagenesis, Insertional | 1 | 2005 | 218 | 0.060 |
Why?
|
| Carcinogens | 1 | 2006 | 384 | 0.060 |
Why?
|
| Intervertebral Disc | 1 | 2004 | 21 | 0.060 |
Why?
|
| Phosphoadenosine Phosphosulfate | 1 | 2004 | 1 | 0.060 |
Why?
|
| Anhydrides | 1 | 2004 | 10 | 0.060 |
Why?
|
| Phosphoric Acids | 1 | 2004 | 3 | 0.060 |
Why?
|
| United States Occupational Safety and Health Administration | 1 | 2004 | 5 | 0.060 |
Why?
|
| Construction Materials | 1 | 2004 | 5 | 0.060 |
Why?
|
| Noise, Occupational | 1 | 2004 | 6 | 0.060 |
Why?
|
| Football | 1 | 2004 | 37 | 0.060 |
Why?
|
| Silicon Dioxide | 1 | 2004 | 50 | 0.060 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2007 | 494 | 0.060 |
Why?
|
| Inhalation Exposure | 1 | 2004 | 41 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2012 | 2295 | 0.060 |
Why?
|
| Phosphorus | 1 | 2004 | 65 | 0.060 |
Why?
|
| beta-Galactosidase | 2 | 1994 | 211 | 0.060 |
Why?
|
| Vagina | 1 | 2006 | 317 | 0.060 |
Why?
|
| Genes, Suppressor | 1 | 2003 | 25 | 0.060 |
Why?
|
| Neoplasms, Experimental | 2 | 1999 | 750 | 0.060 |
Why?
|
| Catalysis | 1 | 2004 | 250 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 5112 | 0.060 |
Why?
|
| Amides | 1 | 2004 | 123 | 0.060 |
Why?
|
| Organophosphonates | 1 | 2004 | 64 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2004 | 515 | 0.060 |
Why?
|
| Nucleotides | 1 | 2004 | 164 | 0.060 |
Why?
|
| Piperazines | 1 | 2012 | 2101 | 0.060 |
Why?
|
| Viral Plaque Assay | 1 | 2003 | 48 | 0.060 |
Why?
|
| Caspases | 1 | 2006 | 661 | 0.060 |
Why?
|
| RNA, Viral | 1 | 2006 | 671 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 2 | 2010 | 188 | 0.060 |
Why?
|
| Lumbar Vertebrae | 1 | 2004 | 245 | 0.060 |
Why?
|
| Phosphates | 1 | 2004 | 187 | 0.060 |
Why?
|
| Mice, Inbred SENCAR | 2 | 1999 | 13 | 0.060 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 7789 | 0.060 |
Why?
|
| Oligonucleotides | 1 | 2004 | 227 | 0.060 |
Why?
|
| Hemochromatosis Protein | 1 | 2002 | 23 | 0.060 |
Why?
|
| Oligonucleotide Probes | 2 | 1994 | 130 | 0.050 |
Why?
|
| Vaccination | 1 | 2009 | 1123 | 0.050 |
Why?
|
| Cytosol | 1 | 2003 | 238 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2002 | 45 | 0.050 |
Why?
|
| Biological Transport, Active | 1 | 2002 | 131 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 289 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 4938 | 0.050 |
Why?
|
| Restriction Mapping | 2 | 1994 | 264 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 6009 | 0.050 |
Why?
|
| Disease Progression | 5 | 2014 | 6682 | 0.050 |
Why?
|
| Alphaherpesvirinae | 1 | 2002 | 1 | 0.050 |
Why?
|
| Telomerase | 1 | 2005 | 525 | 0.050 |
Why?
|
| Poxviridae | 1 | 2002 | 7 | 0.050 |
Why?
|
| Osmosis | 1 | 2021 | 18 | 0.050 |
Why?
|
| Water Quality | 1 | 2021 | 8 | 0.050 |
Why?
|
| Drug Costs | 1 | 2023 | 144 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2010 | 2508 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2009 | 7222 | 0.050 |
Why?
|
| Membranes, Artificial | 1 | 2021 | 38 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2002 | 201 | 0.050 |
Why?
|
| Keratin-15 | 1 | 2001 | 4 | 0.050 |
Why?
|
| Bioreactors | 1 | 2021 | 49 | 0.050 |
Why?
|
| Cytokines | 2 | 2008 | 2809 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2004 | 624 | 0.050 |
Why?
|
| Bone-Patellar Tendon-Bone Grafting | 1 | 2021 | 1 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2002 | 88 | 0.050 |
Why?
|
| Occupational Exposure | 1 | 2004 | 244 | 0.050 |
Why?
|
| Cell Survival | 2 | 2010 | 3045 | 0.050 |
Why?
|
| Keratin-5 | 1 | 2001 | 57 | 0.050 |
Why?
|
| Cell Transformation, Viral | 1 | 2002 | 138 | 0.050 |
Why?
|
| Nitrogen | 1 | 2021 | 162 | 0.050 |
Why?
|
| Biopsy | 2 | 2020 | 3443 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2003 | 309 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2015 | 597 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 213 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2002 | 251 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 694 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 8865 | 0.050 |
Why?
|
| Autografts | 1 | 2021 | 165 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2023 | 253 | 0.050 |
Why?
|
| Gallium Radioisotopes | 1 | 2020 | 60 | 0.050 |
Why?
|
| Genes, myc | 1 | 2002 | 358 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2003 | 663 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 915 | 0.050 |
Why?
|
| HIV | 1 | 2002 | 229 | 0.050 |
Why?
|
| Kinetics | 1 | 2003 | 2049 | 0.050 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2020 | 67 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2005 | 1016 | 0.050 |
Why?
|
| Genes, Synthetic | 1 | 1999 | 26 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 4314 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2023 | 651 | 0.050 |
Why?
|
| APOBEC-3G Deaminase | 1 | 2019 | 6 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 1439 | 0.050 |
Why?
|
| Meniscectomy | 1 | 2019 | 2 | 0.040 |
Why?
|
| Aminohydrolases | 1 | 2019 | 7 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2012 | 3518 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 1994 | 1618 | 0.040 |
Why?
|
| Cytosine Deaminase | 1 | 2019 | 39 | 0.040 |
Why?
|
| Recombination, Genetic | 1 | 2002 | 613 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 344 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 2947 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2002 | 546 | 0.040 |
Why?
|
| Homicide | 1 | 2020 | 36 | 0.040 |
Why?
|
| Cartilage Diseases | 1 | 2019 | 23 | 0.040 |
Why?
|
| Cytomegalovirus Vaccines | 1 | 2019 | 7 | 0.040 |
Why?
|
| Transgenes | 1 | 2001 | 557 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2006 | 1146 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2002 | 589 | 0.040 |
Why?
|
| DNA, Complementary | 3 | 2001 | 869 | 0.040 |
Why?
|
| Brain Neoplasms | 2 | 2007 | 4849 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2004 | 636 | 0.040 |
Why?
|
| Violence | 1 | 2020 | 116 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 2403 | 0.040 |
Why?
|
| Glioblastoma | 2 | 2010 | 1797 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2005 | 3033 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2003 | 1144 | 0.040 |
Why?
|
| RNA-Binding Proteins | 2 | 2002 | 984 | 0.040 |
Why?
|
| E2F5 Transcription Factor | 1 | 1998 | 8 | 0.040 |
Why?
|
| Protein Conformation | 2 | 2012 | 1258 | 0.040 |
Why?
|
| A549 Cells | 1 | 2019 | 124 | 0.040 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2018 | 37 | 0.040 |
Why?
|
| Rupture | 1 | 2018 | 61 | 0.040 |
Why?
|
| Retina | 1 | 2002 | 532 | 0.040 |
Why?
|
| Retinoblastoma | 1 | 2000 | 200 | 0.040 |
Why?
|
| Hair | 1 | 1998 | 42 | 0.040 |
Why?
|
| Patellar Ligament | 1 | 2017 | 13 | 0.040 |
Why?
|
| Endosomes | 1 | 2018 | 109 | 0.040 |
Why?
|
| Models, Genetic | 2 | 2015 | 1113 | 0.040 |
Why?
|
| Electrophoresis | 1 | 1997 | 60 | 0.040 |
Why?
|
| Uniparental Disomy | 2 | 2010 | 66 | 0.040 |
Why?
|
| Crosses, Genetic | 1 | 1998 | 241 | 0.040 |
Why?
|
| DNA Primers | 2 | 2011 | 1399 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 665 | 0.040 |
Why?
|
| Physical Chromosome Mapping | 1 | 2017 | 73 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2003 | 904 | 0.040 |
Why?
|
| Lunch | 1 | 2017 | 13 | 0.040 |
Why?
|
| Meniscus | 1 | 2017 | 2 | 0.040 |
Why?
|
| Second-Look Surgery | 1 | 2017 | 14 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2018 | 460 | 0.040 |
Why?
|
| Animals, Newborn | 2 | 2001 | 1338 | 0.040 |
Why?
|
| Transcription Elongation, Genetic | 1 | 2017 | 25 | 0.040 |
Why?
|
| DNA Probes | 1 | 1997 | 217 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 144 | 0.040 |
Why?
|
| Diploidy | 1 | 2017 | 114 | 0.040 |
Why?
|
| Bacteria | 1 | 2021 | 611 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 1998 | 521 | 0.040 |
Why?
|
| Urography | 1 | 2017 | 43 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2018 | 699 | 0.040 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2017 | 34 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 550 | 0.040 |
Why?
|
| Lymphoma | 1 | 2006 | 1467 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 2291 | 0.040 |
Why?
|
| Quality Control | 1 | 2018 | 457 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2000 | 1082 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2017 | 115 | 0.040 |
Why?
|
| Glutamine | 1 | 2019 | 299 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 4757 | 0.040 |
Why?
|
| HLA-DRB1 Chains | 1 | 2017 | 82 | 0.040 |
Why?
|
| Luciferases | 2 | 1997 | 445 | 0.040 |
Why?
|
| Knee Injuries | 1 | 2017 | 63 | 0.040 |
Why?
|
| Proteolysis | 1 | 2019 | 370 | 0.040 |
Why?
|
| Cartilage | 1 | 2017 | 128 | 0.040 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2016 | 46 | 0.040 |
Why?
|
| Nutrition Policy | 1 | 2017 | 111 | 0.040 |
Why?
|
| Hematuria | 1 | 2017 | 85 | 0.040 |
Why?
|
| Fungal Proteins | 1 | 1997 | 254 | 0.040 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2017 | 174 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5178 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2007 | 6942 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2000 | 1070 | 0.030 |
Why?
|
| MafB Transcription Factor | 1 | 2015 | 12 | 0.030 |
Why?
|
| Schools | 1 | 2017 | 233 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2012 | 2307 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2015 | 19 | 0.030 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2016 | 160 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 756 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2017 | 226 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2018 | 745 | 0.030 |
Why?
|
| Herpes Simplex Virus Protein Vmw65 | 1 | 1994 | 23 | 0.030 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2016 | 159 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2017 | 481 | 0.030 |
Why?
|
| Sarcoma | 1 | 2005 | 1725 | 0.030 |
Why?
|
| Hospitals | 1 | 2018 | 485 | 0.030 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 162 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2803 | 0.030 |
Why?
|
| Information Seeking Behavior | 1 | 2015 | 34 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 257 | 0.030 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2015 | 110 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 403 | 0.030 |
Why?
|
| Mitosis | 1 | 2017 | 615 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 848 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1997 | 798 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2015 | 171 | 0.030 |
Why?
|
| Introns | 2 | 2009 | 432 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 1999 | 755 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 552 | 0.030 |
Why?
|
| Adenovirus E4 Proteins | 1 | 1993 | 9 | 0.030 |
Why?
|
| Germany | 1 | 2014 | 111 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 1021 | 0.030 |
Why?
|
| Microinjections | 1 | 1993 | 96 | 0.030 |
Why?
|
| Pregnancy | 2 | 2019 | 7573 | 0.030 |
Why?
|
| Species Specificity | 1 | 2015 | 777 | 0.030 |
Why?
|
| Minnesota | 1 | 2013 | 93 | 0.030 |
Why?
|
| Child | 4 | 2019 | 29154 | 0.030 |
Why?
|
| G1 Phase | 1 | 1994 | 285 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 120 | 0.030 |
Why?
|
| Osteonectin | 1 | 2013 | 53 | 0.030 |
Why?
|
| HIV Infections | 1 | 2006 | 2134 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2013 | 170 | 0.030 |
Why?
|
| Microscopy, Interference | 1 | 2012 | 16 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2013 | 64 | 0.030 |
Why?
|
| Galvanic Skin Response | 1 | 2012 | 18 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2016 | 461 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 10001 | 0.030 |
Why?
|
| Focus Groups | 1 | 2013 | 256 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 2316 | 0.030 |
Why?
|
| Glucose | 1 | 2019 | 1248 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2015 | 556 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 860 | 0.030 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 43 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2012 | 123 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2003 | 2074 | 0.030 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1992 | 173 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 3639 | 0.030 |
Why?
|
| Bone Marrow | 2 | 2013 | 2358 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2014 | 575 | 0.030 |
Why?
|
| Up-Regulation | 1 | 1998 | 2450 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2013 | 185 | 0.030 |
Why?
|
| Metribolone | 1 | 2011 | 48 | 0.030 |
Why?
|
| Social Support | 1 | 2015 | 560 | 0.030 |
Why?
|
| Connexin 26 | 1 | 2001 | 21 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2011 | 83 | 0.030 |
Why?
|
| Precancerous Conditions | 1 | 1998 | 1058 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 292 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 314 | 0.030 |
Why?
|
| Claudin-1 | 1 | 2011 | 32 | 0.030 |
Why?
|
| Mice, Nude | 2 | 1999 | 4307 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 697 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 2843 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 1085 | 0.020 |
Why?
|
| Tight Junctions | 1 | 2011 | 56 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2011 | 239 | 0.020 |
Why?
|
| Karyotyping | 1 | 2013 | 1022 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 209 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 392 | 0.020 |
Why?
|
| Laminin | 1 | 2001 | 194 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 854 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2004 | 287 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2010 | 23 | 0.020 |
Why?
|
| Plicamycin | 1 | 2010 | 30 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1077 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2012 | 229 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2010 | 41 | 0.020 |
Why?
|
| RNA, Long Noncoding | 1 | 2016 | 598 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2218 | 0.020 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2010 | 24 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 10035 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2001 | 259 | 0.020 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2010 | 38 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 1294 | 0.020 |
Why?
|
| Electroshock | 1 | 2009 | 46 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2001 | 4078 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2001 | 248 | 0.020 |
Why?
|
| Placenta | 1 | 1994 | 516 | 0.020 |
Why?
|
| Poverty | 1 | 2013 | 471 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2001 | 360 | 0.020 |
Why?
|
| Electrodes | 1 | 2009 | 116 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 1489 | 0.020 |
Why?
|
| Research Design | 1 | 2017 | 1544 | 0.020 |
Why?
|
| Bortezomib | 1 | 2011 | 543 | 0.020 |
Why?
|
| DNA Replication | 1 | 1993 | 744 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2001 | 621 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 693 | 0.020 |
Why?
|
| Age of Onset | 1 | 2011 | 827 | 0.020 |
Why?
|
| Homeostasis | 1 | 1994 | 950 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 3260 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2001 | 492 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2009 | 170 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2009 | 259 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2009 | 225 | 0.020 |
Why?
|
| Cues | 1 | 2009 | 192 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2001 | 1008 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2010 | 2027 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2012 | 966 | 0.020 |
Why?
|
| Cadherins | 1 | 2001 | 660 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 1648 | 0.020 |
Why?
|
| Collagen | 1 | 2001 | 752 | 0.020 |
Why?
|
| Deubiquitinating Enzyme CYLD | 1 | 2007 | 23 | 0.020 |
Why?
|
| Odontometry | 1 | 2007 | 1 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2012 | 1732 | 0.020 |
Why?
|
| WW Domain-Containing Oxidoreductase | 1 | 2007 | 50 | 0.020 |
Why?
|
| Esthetics, Dental | 1 | 2007 | 16 | 0.020 |
Why?
|
| Prednisone | 1 | 2010 | 984 | 0.020 |
Why?
|
| beta Catenin | 1 | 2001 | 688 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 1910 | 0.020 |
Why?
|
| Melphalan | 1 | 2010 | 834 | 0.020 |
Why?
|
| Azacitidine | 1 | 2013 | 1149 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1998 | 3230 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2006 | 6 | 0.020 |
Why?
|
| Ionomycin | 1 | 2006 | 34 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 4758 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2006 | 102 | 0.020 |
Why?
|
| Vincristine | 1 | 2010 | 1511 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 2001 | 1213 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2010 | 1005 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 184 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2006 | 394 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2006 | 311 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 1165 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2010 | 1450 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 13658 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 11538 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 2004 | 49 | 0.020 |
Why?
|
| Clone Cells | 1 | 2006 | 555 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2004 | 68 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2006 | 284 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 4638 | 0.010 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 4557 | 0.010 |
Why?
|
| Sex Ratio | 1 | 2003 | 15 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 460 | 0.010 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2003 | 17 | 0.010 |
Why?
|
| Housing | 1 | 2004 | 61 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2017 | 3341 | 0.010 |
Why?
|
| Cell Movement | 1 | 2001 | 2466 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2003 | 56 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2010 | 929 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 2004 | 338 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2003 | 300 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2010 | 3001 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2010 | 3005 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2003 | 266 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2004 | 360 | 0.010 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2001 | 30 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2003 | 675 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 1688 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 7551 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2000 | 224 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 995 | 0.010 |
Why?
|
| Templates, Genetic | 1 | 1999 | 86 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 1904 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 844 | 0.010 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 1998 | 36 | 0.010 |
Why?
|
| Ribonucleoproteins | 1 | 1998 | 123 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1998 | 195 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2000 | 716 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 1519 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2001 | 613 | 0.010 |
Why?
|
| Insecta | 1 | 1997 | 76 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2000 | 1869 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1998 | 534 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 15694 | 0.010 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 1993 | 7 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1993 | 362 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2000 | 3981 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 1992 | 132 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1993 | 997 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 4971 | 0.010 |
Why?
|